Latest Articles and Analysis

Patients face multiple monkeypox barriers: disorganized state websites, limited vaccine access, reporting gaps.

ADAP Fireside Chat addresses counterfeit medications, 340B reform, and public health workforce sustainability.

S.4395 would divert Ryan White resources from PLWHA to PrEP, threatening the safety net for vulnerable populations.

85,000+ fake HIV medication bottles distributed through counterfeiting rings endanger patient safety.

West Virginia's fragmented HIV services across four entities creates barriers; centralization needed.

Health misinformation undermines vaccine confidence, perpetuates stigma, and drives poor policy decisions.

Restrictions on abortion and transgender care represent broader attacks on medication access as human right.

Pharmaceutical industry changes to 340B implementation impact pricing and accessibility for covered entities.

AMA survey: 93% of providers say prior authorizations delay care with 91% reporting negative clinical impact.

Copay accumulator programs block patient assistance from counting toward deductibles; HELP Copays Act needed.

Flurona co-infections highlight information challenges amid pandemic fatigue and misinformation.

CDC updates STI treatment guidelines; ACIP recommends universal adult HBV vaccination and HPV catch-up.

CANN reflects on 2021 advocacy spanning 340B drug pricing, HIV, hepatitis C, and substance use disorder policy.

Final installment addressing 340B reform needs: transparency, accountability, and contract pharmacy concerns.

Analyzes the role of contract pharmacies and intermediaries in 340B drug distribution and patient access.

Examines how 340B program expansion correlates with declining hospital charity care for vulnerable patients.

Explores accountability mechanisms in the 340B program and oversight requirements for patient protection.

Explains why transparency in 340B operations is critical for program integrity and patient access.

Introduces the 340B Drug Discount Program: its history, purpose, and significance for medication access.

Payers restrict HCV treatment through utilization management; patient assistance programs fill the critical gap.